E-MTAB-1809 - Transcriptional profiling by array of human type II and type III myxoid liposarcoma xenograft adipose tissues in athymic nude mice harvested at different time points after trabectidin treatment
Released on 10 December 2013, last updated on 3 June 2014
To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes we have developed and characterized two MRCL xenografts differing for the breakpoint of the fusion gene FUS- HOP, respectively of type II and III. Transcription profiling experiments were carried out after trabectidin treatment in four separate time points (control, 24h after the first dose, 24h after the third dose, and 15 days after the third dose) for both types of xenografts in order to identify genes and pathways involved with the mechanisms of action of trabectedin in MRCL.
transcription profiling by array, co-expression, compound treatment, in vivo, replicate
Mode of action of trabectedin in myxoid liposarcomas. Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, DIncalci M. Oncogene , PMID:24213580